EU regulator backs use of Novo's Wegovy for obesity-related heart condition

Wegovy produced by Danish firm Novo Nordisk.

The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with obesity, the Danish drugmaker said on Thursday.

This marks the regulator's second backing for a use of Wegovy beyond weight loss and further strengthens Novo's case that the medicine has multiple health benefits.